A Randomized, Double-blind, Phase II Study of RAD001 10 mg/d plus Best Supportive Care versus Placebeo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocri
04/04/2008 - 04/30/2011 (PI)Novartis Pharmaceuticals Corporation
A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care vs placebo, plus best best supportive care in patients with advanced gastric cance
03/16/2010 - 02/28/2011 (PI)Novartis Pharmaceuticals Corporation
A Phase II, Multi-center, Open-label Trial to Evaluate the Efficacy and Safety of DAVANAT in Combination with 5-Fluorouracil when Administered as First Line Chemotherapy in Patients Advanced Bili
07/05/2007 - 07/04/2010 (PI)Pro-Pharmaceuticals, Inc.
A Randomized, Open-Label Trial Comparing Two Avastin (bevacizumab)- Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer
05/17/2006 - 12/31/2009 (PI)Genentech, Inc.
Enhancing Collectin Mediated Host Defense
04/01/1998 - 03/31/2003 (PI)NIH/National Heart, Lung, and Blood Institute
5 R01 HL58910 04
An Open Label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with HighDose 5-Fluoraouracil (5FU) vs. Gemcitabine for Treatment of Patients with Advanced Pancreatic Cancer
12/01/2001 - 11/30/2002 (PI)Pro-Neuron
Merck 937: A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizu
08/15/2019 - 08/31/2024 (PI)Merck
Lexicon: A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (telotristat …
02/06/2020 - 02/05/2023 (PI)Lexicon Pharmaceuticals, Inc.
NGM 120: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL…
01/03/2020 - 01/02/2023 (PI)NGM Biopharmaceuticals, Inc.
Enhancing Collectin Mediated Defense Against Influenza
07/01/2019 - 12/31/2020 (PI)National Heart, Lung, and Blood Institute/NIH/DHHS National Institutes R01HL069031-17
EL CENTRO: Engaging Latinos in the CENter of Cancer TReatment Options
09/01/2019 - 08/31/2020 (PI)Dana Farber Cancer Institute National Cancer Inst5U54CA156732-07
Pulmonary Epithelial Dynamics and Innate Host Defense
12/07/2017 - 11/30/2019 (PI)University of Cincinnati National Institutes 1R01HL135122-01A1
The JANUS 1 Study
08/26/2015 - 08/31/2019 (PI)Incyte Corporation
11/17/2017 - 03/31/2019 (PI)Merck
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib of Placebo in Comb…
01/15/2015 - 01/31/2019 (PI)Incyte Corporation
Enhancing Collectin Medicated Defense Against Influenza
08/11/2011 - 06/30/2015 (PI)NIH-NHLBI5R01 HL069031-12
Showing 10 of 17 results.
Show All Results